The stock of CRISPR Therapeutics AG (NASDAQ: CRSP) has increased by 0.49 when compared to last closing price of 45.03.Despite this, the company has seen a loss of -4.70% in its stock price over the last five trading days. fool.com reported 2024-09-05 that CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech’s bottom line starts to show significant improvement.
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?
The stock has a 36-month beta value of 1.68. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRSP is 81.46M, and at present, short sellers hold a 21.08% of that float. On September 06, 2024, the average trading volume of CRSP was 1.29M shares.
CRSP’s Market Performance
CRSP stock saw a decrease of -4.70% in the past week, with a monthly decline of -8.27% and a quarterly a decrease of -24.23%. The volatility ratio for the week is 3.81%, and the volatility levels for the last 30 days are 4.13% for CRISPR Therapeutics AG (CRSP).. The simple moving average for the past 20 days is -5.35% for CRSP’s stock, with a -26.96% simple moving average for the past 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Needham repeating the rating for CRSP by listing it as a “Buy.” The predicted price for CRSP in the upcoming period, according to Needham is $84 based on the research report published on August 06, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $90. The rating they have provided for CRSP stocks is “Buy” according to the report published on August 02nd, 2024.
CRSP Trading at -13.77% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.33% of loss for the given period.
Volatility was left at 4.13%, however, over the last 30 days, the volatility rate increased by 3.81%, as shares sank -4.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.12% lower at present.
During the last 5 trading sessions, CRSP fell by -4.70%, which changed the moving average for the period of 200-days by -23.59% in comparison to the 20-day moving average, which settled at $47.71. In addition, CRISPR Therapeutics AG saw -27.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Bruno Julianne, who sale 3,366 shares at the price of $56.09 back on Jun 21 ’24. After this action, Bruno Julianne now owns 6,745 shares of CRISPR Therapeutics AG, valued at $188,799 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 19,582 shares at $59.91 during a trade that took place back on Apr 15 ’24, which means that Kulkarni Samarth is holding 208,122 shares at $1,173,232 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -1.76 for the present operating margin
- 0.24 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -1.32. The total capital return value is set at -0.16. Equity return is now at value -14.00, with -11.72 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -19.93.
Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 17.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.73.
Conclusion
To sum up, CRISPR Therapeutics AG (CRSP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
